Life Insurance
Life insurers benefiting from improved mortality expectations across covered populations.
Why GLP-1 Matters Here
Obesity is a primary driver of the leading causes of death in the United States: cardiovascular disease, type 2 diabetes, certain cancers, sleep apnea with cardiac complications. A population-wide reduction in obesity rates therefore has direct and quantifiable effects on mortality curves that life insurers model actuarially.
What the Data Shows
Munich Re analyzed a de-identified dataset of 41 million lives with linked prescription and mortality data from 2015 to 2025 and projects 0.2 to 0.5 percent annual mortality improvement attributable to GLP-1 adoption over a 20-year period. Swiss Re projects up to 6.4 percent cumulative US mortality reduction by 2045.
RGA's central scenario projects 3.5 percent US mortality reduction by 2045 with an upside scenario reaching 8.8 percent.
Analysis
These figures are material to life insurance pricing and reserve assumptions: when projected mortality improves, insurers can price policies lower while maintaining margin, or hold pricing and expand margin, and reserves set aside against future claims can be reduced. These figures represent a repricing event unfolding in slow motion across the industry's actuarial assumptions.
Recent Coverage
GLP-1 therapies and mortality risk: Implications for life insurers
Stopping GLP-1 drugs can quickly erase cardiovascular benefits
GLP-1 drugs combined with healthy lifestyle habits linked with reduced cardiovascular risk among diabetes patients
Research Findings
Curated citations from peer-reviewed studies and institutional research
Annual mortality improvement rate of 0.2% to 0.5% attributable to GLP-1 adoption projected over 20-year period
% annual mortality improvement rate attributable to GLP-1 adoption (high estimate)
Central scenario projects 3.5% U.S. mortality reduction by 2045, with up to 8.8% reduction possible
% projected U.S. mortality reduction by 2045 (central scenario)
Data Sources
Research citations only — no government economic data source for this vertical
Industry Fundamentals
No government agency tracks this vertical's performance directly. This vertical is monitored through research citations and search intelligence only.
Research Citations
Munich Re, RGA
Peer-reviewed studies, investment bank analysis, and institutional surveys. Manually curated and updated monthly.
Get updates on Life Insurance
Monthly data updates when this vertical's citations and industry data change.